Providing a platform for diverse viewpoints on political transitions and societal needs. Public Services:
While Addis Lisan is indispensable for hyper-local city news, readers often pair it with other prominent publications to get a 360-degree view of Ethiopian affairs.
┌─────────────────────────────────────────────────────────────┐ │ ETHIOPIAN MEDIA LANDSCAPE │ └──────────────────────────────┬──────────────────────────────┘ │ ┌───────────────────────┼───────────────────────┐ ▼ ▼ ▼ ┌──────────────┐ ┌──────────────┐ ┌────────────────┐ │ Municipal │ │ Private/ │ │ Online/ │ │ / State │ │ Bi-Lingual │ │ Specialized │ ├──────────────┤ ├──────────────┤ ├────────────────┤ │ • Addis Lisan│ │ • The │ │ • Addis │ │ • Addis │ │ Reporter │ │ Standard │ │ Zemen │ │ • Capital │ │ • Fortune │ └──────────────┘ └──────────────┘ └────────────────┘ Addis lisan news paper amharic
The latest editions of Addis Lisan typically highlight metropolitan progress and regional governance. Key areas of focus for today's readers include: addis lisan newspaper today
In-depth documentation of cultural infrastructure designed to boost regional tourism. 2. Local Economy and Business Notices
: In-depth coverage of parliamentary proceedings, government policies, and national elections.
Unlike privately-owned economic or political journals in East Africa, Addis Lisan operates with a specific metropolitan framework. It is published primarily in Amharic, functioning as the key media channel for the municipal government to communicate urban renewal strategies, mega-infrastructure timelines, and civic updates directly to the residents of Addis Ababa. Providing a platform for diverse viewpoints on political
As the country navigates a transformative period marked by major national elections and structural macroeconomic updates, turning to offers critical insight into the nation’s rapidly evolving socio-political landscape. 1. Navigating Ethiopia's Historic Election Cycle
: The official owner and operator of the newspaper.
The municipal landscape is currently undergoing major updates regarding property law and urban space utilization. Tracking local municipal notices reveals critical updates for property owners: Key areas of focus for today's readers include:
Addis Lisan is structurally designed to cater directly to the citizens of Addis Ababa and the broader Amharic-speaking public. Unlike national state-run giants or specialized business journals like Addis Fortune , Addis Lisan centers its editorial lenses primarily on city life, civic engagement, and local administration.
Real-time updates are shared on the Amn-Addis Lisan Facebook page .
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational therapies at the appropriate time and in a clinically appropriate manner for patients.
Outside of our clinical trials, we may provide physician-requested expanded access to its investigational products under limited situations. This is initiated when the primary purpose is to diagnose, prevent, or treat a serious condition in a patient, which is different from a clinical trial where more comprehensive safety and efficacy data are collected. At Genelux, we recognize and understand the need for an early/expanded access policy for patients who have serious or immediately life-threatening disease and have limited available treatment options.
The request for access to a Genelux investigational drug will be considered only if the patient is an eligible patient, meaning:
In addition, prior to setting up an expanded access program or granting a request from an eligible patient’s physician, Genelux will consider whether:
At this time, based on these factors, Genelux believes that participation in one of our clinical trials is the only appropriate way to access our investigational therapies.
If the investigational drug is approved by a regulatory agency for commercial use, including provisional approval, existing expanded access programs will be phased out or modified accordingly.
Patients interested in seeking an expanded access to a Genelux investigative drug should talk to their physician. All requests must be made by the patient’s treating physician by email at . We will, in general, acknowledge receipt of a request for expanded access within five business days. We may ask for more detailed information to fully evaluate a request.
The request for access to an investigative drug can only be considered if the requesting physician agrees to obtain applicable regulatory and ethics committee approvals. We may deny access if the treating physician cannot guarantee an appropriate storage and handling of the investigative drug, which typically requires a temperature controlled deep freezer and follows Biosafety Level 2 safety procedures and precautions. The treating physician must agree to comply with regulatory obligations, including safety monitoring and reporting.
For more information on expanded access from the FDA, click here.